Covington Advises Underwriters in $138 Million Stock Offering by Repligen

NEW YORK—Covington advised the underwriters in a $138 million follow-on public offering of common stock by Repligen Corporation. Covington previously represented the underwriters in Repligen's $115 million convertible note offering in May 2016.

Repligen is a bioprocessing company focused on the manufacture of Protein A ligands, cell culture growth factors, and filtration and chromatography products used by life science companies to manufacture and purify biologic drugs such as monoclonal antibodies, recombinant proteins, and vaccines.

The Covington corporate team was led by Don Murray, Brian Rosenzweig, Matt Gehl, and John Mei.